Metformin prevents cisplatin-induced cognitive impairment and brain damage in mice

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Zhou, Wenjun ^a,b   Kavelaars, Annemieke ^a   Heijnen, Cobi J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; METFORMIN; ANTIDIABETIC AGENT; MYELIN BASIC PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN DAMAGE; BRAIN TISSUE; C57BL 6 MOUSE; CELL ACTIVATION; CINGULATE GYRUS; COGNITIVE DEFECT; CONTROLLED STUDY; DENDRITIC SPINE; DRUG EFFECT; FEMALE; IMMUNOHISTOCHEMISTRY; MICROGLIA; MOUSE; MULTIPLE CYCLE TREATMENT; NEUROPROTECTION; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PYRAMIDAL NERVE CELL; SOCIAL DISCRIMINATION; TASK PERFORMANCE; VON FREY TEST; WHITE MATTER; ANIMAL; ANIMAL BEHAVIOR; BRAIN; BRAIN INJURIES; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; COGNITION DISORDERS; DISEASE MODEL; DRUG EFFECTS; HYPERALGESIA; METABOLISM; PATHOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN INJURIES; CISPLATIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; HYPERALGESIA; HYPOGLYCEMIC AGENTS; METFORMIN; MICE; MICE, INBRED C57BL; MYELIN BASIC PROTEIN; PYRAMIDAL CELLS;

EID: 84962157654     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151890     Document Type: Article

References (61)

1. de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22:561-570. doi: 10.1158/1055-9965. EPI-12-1356 PMID: 23535024
2. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7:192-201. PMID: 17318212
3. O'Farrell E, MacKenzie J, Collins B. Clearing the air: a review of our current understanding of "chemo fog". Curr Oncol Rep. 2013;15:260-269. doi: 10.1007/s11912-013-0307-7 PMID: 23483375
4. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012;12:267-275. doi: 10.1007/s 11910-012-0264-9 PMID: 22453825
5. Selamat MH, Loh SY, Mackenzie L, Vardy J. Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications. PLoS One. 2014;9:e108002. doi: 10.1371/journal.pone.0108002 PMID: 25259847
6. Moore HC. An Overview of Chemotherapy-Related Cognitive Dysfunction, or 'Chemobrain'. Oncology (Williston Park). 2014;28:797-804
7. Vardy J, 2 Tannock I. Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol. 2007;63:183-202. PMID: 17678745
8. Simo M, Rifa-Ros X, Rodriguez-Fornells A, Bruna J. Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev. 2013;37:1311-1321. doi: 10.1016/j. neubiorev. 2013.04.015 PMID: 23660455
9. Simo M, Root JC, Vaquero L, Ripolles P, Jove J, Ahles T, et al. Cognitive and Brain Structural Changes in Lung Cancer Population. JThoracOncol. 2015;10(1):38-45 doi: 10.1097/JTO.0000000000000345 PMID: 25325778
10. Lepage C, Smith AM, Moreau J, Barlow-Krelina E, Wallis N, Collin B, et al. A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. Springerplus. 2014;3:444. doi: 10.1186/2193-1801-3-444 PMID: 25184110
11. Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26:102-113. doi: 10.3109/09540261.2013. 864260 PMID: 24716504
12. Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2008;110:143-152. PMID: 17674194
13. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25:3866-3870. PMID: 17761972
14. Kesler SR, Wefel JS, Hosseini SM, Cheung M, Watson CL, Hoeft F. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc Natl Acad Sci USA. 2013;110:11600-11605. doi: 10.1073/pnas.1214551110 PMID: 23798392
15. Winocur G, Wojtowicz JM, Tannock IF. Memory loss in chemotherapy-treated rats is exacerbated in high-interference conditions and related to suppression of hippocampal neurogenesis. Behav Brain Res. 2014;281:239-244. doi: 10.1016/j.bbr.2014.12.028 PMID: 25529185
16. Winocur G, Henkelman M, Wojtowicz JM, Zhang H, Binns MA, Tannock IF. The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clin Cancer Res. 2012;18:3112-3121. doi: 10.1158/1078-0432. CCR-12-0060 PMID: 22467680
17. Briones TL, Woods J. Dysregulation in myelination mediated by persistent neuroinflammation: possible mechanisms in chemotherapy-related cognitive impairment. Brain Behav Immun. 2014;35:23-32. doi: 10.1016/j.bbi.2013.07.175 PMID: 23916895
18. Vichaya EG, Chiu GS, Krukowski K, Lacourt TE, Kavelaars A, Dantzer R, et al. Mechanisms of chemotherapy-induced behavioral toxicityies. Front Neurosci. 2015;9:131 doi: 10.3389/fnins.2015.00131 PMID: 25954147
19. Whitney KA, Lysaker PH, Steiner AR, Hook JN, Estes DD, Hanna NH. Is "chemobrain" a transient state? A prospective pilot study among persons with non-small cell lung cancer. J Support Oncol. 2008;6:313-321. PMID: 18847074
20. Gan HK, Bernstein LJ, Brown J, Ringash J, Vakilha M, Wang L, et al. Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;81:126-134. doi: 10.1016/j.ijrobp. 2010.05.004 PMID: 20708851
21. Fung C, Vaughn DJ. Complications associated with chemotherapy in testicular cancer management. Nat Rev Urol. 2011;8:213-222. doi: 10.1038/nrurol.2011.26 PMID: 21403662
22. Schagen SB, Boogerd W, Muller MJ, Huinink WT, Moonen L, Meinhardt W, et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol. 2008;47:63-70. PMID: 17934892
23. Skoogh J, Steineck G, Stierner U, Cavallin-Stahl E, Wilderang U, Wallin A, et al. Testicular-cancer survivors experience compromised language following chemotherapy: findings in a Swedish populationbased study 3-26 years after treatment. Acta Oncol. 2012;51:185-197. doi: 10.3109/0284186X.2011. 602113 PMID: 21851186
24. Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3342-3350. doi: 10.1200/JCO.2012. 46.1764 PMID: 23816967
25. Bost F, Sahra IB, Le Marchand-Brustel Y, Tanti JF. (2012) Metformin and cancer therapy. CurrOpin Oncol 24:103-108. doi: 10.1097/CCO.0b013e32834d8155 PMID: 22123231
26. Hinduja S, Kraus KS, Manohar S, Salvi RJ. D-Methionine Protects Against Cisplatin-Induced Neurotoxicity in the Hippocampus of the Adult Rat. Neurotox Res. 2015;27(3):199-204 doi: 10.1007/s12640-014-9503-y PMID: 25488710
27. Manohar S, Jamesdaniel S, Salvi R. Cisplatin inhibits hippocampal cell proliferation and alters the expression of apoptotic genes. Neurotox Res. 2014;25:369-380. doi: 10.1007/s12640-013-9443-y PMID: 24277158
28. Song TY Chen CL, Liao JW, Ou HC, Tsai MS. Ergothioneine protects against neuronal injury induced by cisplatin both in vitro and in vivo. Food Chem Toxicol. 2010;48(12):3492-3499 doi: 10.1016/j.fct. 2010.09.030 PMID: 20932872
29. Giridharan VV, Thandavarayan RA, Bhilwade HN, Ko KM, Watanabe K, Konishi T. Schisandrin B, attenuates cisplatin-induced oxidative stress, genotoxicity and neurotoxicity through modulating NF-kappaB pathway in mice. Free Radic Res. 2012;46:50-60 doi: 10.3109/10715762.2011.638291 PMID: 22059853
30. Mao-Ying QL, Kavelaars A, Krukowski K, Huo XJ, Zhou W, Price TJ, et al. The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model. PLoSOne, 2014;9:e100701. doi: 10.1371/journal.pone.0100701 PMID: 24955774
31. Labuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopien B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep. 2010;62:956-965. PMID: 21098880
32. Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E, Schwab M. Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci. 2013;34(2):126-135 doi: 10.1016/j.tips.2012.11.005 PMID: 23277337
33. Le Merrer J, Rezai X, Scherrer G, Becker JAJ, Kieffer B. (2013) Impaired hippocampus dependent and facilitated striatum-dependent behaviors in mice lacking the delta opioid receptor. Neuropsychopharmacology 38(6):1050-1059 doi: 10.1038/npp. 2013.1 PMID: 23303070
34. Engelmann M, Hädicke, Noack J. Testing declarative memory in laboratory rats and mice using the nonconditioned social discrimination procedure. Nature Protocols. 2011;6:1152-1162 doi: 10.1038/nprot.2011.353 PMID: 21799485
35. Wang H, Heijnen CJ, van Velthoven CTJ, Willemen HLDM, Ishikawa Y, Zhang X, et al. Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain. J Clin Invest. 2013;123:5023-5034. doi: 10.1172/JCI66241 PMID: 24231349
36. Donega V, van Velthoven CTJ, Nijboer CH, van Bel F, Kas MJH, Kavelaars A, et al. Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. PLoSOne. 2013;8(1):e51253 doi: 10.1371/journal.pone.0051253 PMID: 23300948
37. Bevins RA, Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. Nat Protoc. 2006;1:1306-1311. PMID: 17406415
38. Guterstam A, Björnsdoter M, Gentile G, Ehrsson HH. Posterior cingulate cortex integrates the senses of self-location and body ownership. Current Biology. 2015;25(11):1416-1425
39. Miller AM, Vedder L, Law LM, Smith DM. Cues, context, and long-term memory: the role of the retrosplenital cortex in spatial cognition. Frontiers in Human Neuroscience. 2014;8:586 doi: 10.3389/fnhum.2014.00586 PMID: 25140141
40. Yoon SY, Robinson CR, Zhang H, Dougherty PM. Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity. J Pain. 2013;14:205-214. doi: 10.1016/j.jpain. 2012.11.002 PMID: 23374942
41. Di Cesare Mannelli L, Pacini A, Micheli L, Tani A, Zanardelli M, Ghelardini C. Glial role in oxaliplatininduced neuropathic pain. Exp Neurol. 2014;261:22-33. doi: 10.1016/j.expneurol.2014.06.016 PMID: 24967684
42. Robinson CR, Zhang H, Dougherty PM. Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat. Neuroscience. 2014;274:308-317. doi: 10.1016/j.neuroscience.2014.05.051 PMID: 24905437
43. Bourne JN, Harris KM. Balancing structure and function at hippocampal dendritic spines. Annu Rev Neurosci. 2008;31:47-67. doi: 10.1146/annurev. neuro.31.060407.125646 PMID: 18284372
44. Lee KF, Soares C, Beique JC. Examining form and function of dendritic spines. Neural Plast. 2012;2012:704103. doi: 10.1155/2012/704103 PMID: 22577585
45. Yuste R. Dendritic spines and distributed circuits. Neuron. 2011;71:772-781. doi: 10.1016/j.neuron. 2011.07.024 PMID: 21903072
46. Ultanir SK, Kim JE, Hall BJ, Deerinck T, Ellisman M, Ghosh A. Regulation of spine morphology and spine density by NMDA receptor signaling in vivo. Proc Natl Acad Sci USA. 2007;104:19553-19558. PMID: 18048342
47. Jiang T, Yu JT, Zhu XC, Wang HF, Tan MS, Cao L, et al. Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemiaby pre-activation of AMPK-dependentautophagy. Br J Pharmacol. 2014;171:3146-3157. doi: 10.1111/bph.12655 PMID: 24611741
48. Li J, Benashski SE, Venna VR, McCullough LD. Effects of metformin in experimental stroke. Stroke. 2010;41:2645-2652. doi: 10.1161/STROKEAHA.110.589697 PMID: 20847317
49. Liu Y, Tang G, Li Y, Wang Y, Chen X, Gu X, et al. Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion. J Neuroinflammation. 2014;11:177. doi: 10.1186/s12974-014-0177-4 PMID: 25315906
50. Park HJ, Stokes JA, Pirie E, Skahen J, Shtaerman Y, Yaksh TL. Persistent Hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor3: the effects of gabapentin, ketorolac, andetanercept. Anesth Analg. 2013;116(1):224-231 doi: 10.1213/ANE.0b013e31826e1007 PMID: 23223118
51. Valero T. Mitochondrial biogenesis: pharmacological approaches. Curr Pharm Des. 2014;20:5507-5509. PMID: 24606795
52. Chung MM, Chen YL, Pei D, Cheng YC, Sun B, Nicol CJ, et al. The neuroprotective role of metformin in advanced glycation end product treated human neural stem cells is AMPK-dependent. Biochim Biophys Acta. 2015;1852:720-731. doi: 10.1016/j.bbadis.2015.01.006 PMID: 25595658
53. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3:1451-1461.
54. Wu L, Zhu J, Prokop LJ, Murad MH. Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies. Sci Rep. 2015;5:10147. doi: 10.1038/srep10147 PMID: 26076034
55. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8:e71583. doi: 10.1371/journal.pone.0071583 PMID: 23936520
56. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoSOne. 2012;7:e33411. doi: 10.1371/journal.pone.0033411 PMID: 22448244
57. Melemedjian OK, Yassine HN, Shy A, Price TJ. Proteomic and functional annotation analysis of injured peripheral nerves reveals ApoE as a protein upregulated by injury that is modulated by metformin treatment. Mol Pain. 2013;9:14. doi: 10.1186/1744-8069-9-14 PMID: 23531341
58. Melemedjian OK, Asiedu MN, Tillu DV, Sanoja R, Yan J, Lark A, et al. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain. 2011;7:70. doi: 10.1186/1744-8069-7-70 PMID: 21936900
59. Yoon SH, Han EJ, Sung JH, Chung SH. Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice. Biol Pharm Bull. 2007;30:2196-2200. PMID: 17978500
60. Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care. 2010;33:156-161. doi: 10.2337/dc09-0606 PMID: 19846797
61. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668-2675. doi: 10.1001/jama.2014. 15298 PMID: 25536258